Our findings suggest that assessing CXCR5 and LAG‐3 expression in peripheral blood CD8+ T cells in peripheral blood CD8+ T cells could provide additional prognostic value beyond the traditional IPI score, potentially offering a novel approach for risk stratification in DLBCL patients. The gene discussed is CD8A; the disease is diffuse large B-cell lymphoma.